natgillin/translations-raw huggingface dataset:
In renal angiomyolipoma caused by tuberous sclerosis, Votubia has been compared with placebo in one study involving 118 adults.
U slučaju renalnog angiomiolipoma uzrokovanog tuberoznom sklerozom, lijek Votubia uspoređen je s placebom u jednom ispitivanju koje je obuhvatilo 118 odraslih osoba.
In renal transplant patients with severe chronic renal impairment (glomerular filtration rate < 25 mL/min/1.73 m2), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided.
Kod bolesnika s presađenim bubregom i teškim kroničnim oštećenjem bubrega (brzina glomerularne filtracije < 25 ml•min-1•1,73 m2) izvan neposrednog postoperativnog razdoblja, treba izbjegavati doze veće od 1 g primijenjene dvaput dnevno.
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects administered oral olanzapine, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr).
U bolesnika s oštećenjem bubrega (klirens kreatinina < 10 ml/min) koji su primili oralni olanzapin nije bilo značajne razlike u odnosu na zdrave ispitanike u prosječnom poluvremenu eliminacije (37,7 naspram 32,4 sata) ili klirensu (21,2 naspram 25,0 l/h).
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus
U bolesnika s oštećenjem bubrega (klirens kreatinina < 10 ml/min) nije bilo značajne razlike u odnosu na zdrave ispitanike u prosječnom poluvremenu eliminacije (37,7 naspram 32,4 sata) ili klirensu
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hrs) or clearance (21.2 versus 25.0 l/hr).
U bolesnika s oštećenjem bubrega (klirens kreatinina < 10 ml/min) u odnosu na zdrave ispitanike nije bilo značajne razlike u srednjoj vrijednosti poluvremena eliminacije (37,7 naspram 32,4 sata) ili klirensu (21,2 naspram 25,0 l/h).
In repeat dose studies in rodents, effects in a variety of tissues (bone, teeth, nail beds, reproductive organs, haematological tissues, kidney and pancreas) appear related to the pharmacology of VEGFR inhibition and/or disruption of VEGF signalling pathways with most effects occurring at plasma exposure levels below those observed in the clinic.
U ispitivanjima s ponovljenim dozama na glodavcima čini se da su učinci na različita tkiva (kost, zubi, baze noktiju, reproduktivni organi, hematološka tkiva, bubrezi i gušterača) povezani s farmakologijom inhibicije VEGFR i/ili poremećajem signalnog puta VEGF, s najviše učinaka pri nižim razinama izloženosti u plazmi od onih kliničkih.
In repeat-dose toxicity studies, conducted in mice, rats, and dogs, atazanavir-related findings were generally confined to the liver and included generally minimal to mild increases in serum bilirubin and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female mice only, hepatic single- cell necrosis.
U ispitivanjima toksičnosti ponovljenih doza provedenih u miševa, štakora i pasa, nalazi povezani s atazanavirom općenito su bili ograničeni na jetru i obično su uključivali minimalna do blaga povišenja serumskog bilirubina i jetrenih enzima, hepatocelularnu vakuolizaciju i hipertrofiju te, samo u ženki miša, nekrozu pojedinačnih jetrenih stanica.
In repeat-dose toxicity studies, conducted in mice, rats, and dogs, atazanavir-related findings were generally confined to the liver and included generally minimal to mild increases in serum bilirubin and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female mice only, hepatic single- cell necrosis.
U ispitivanjima toksičnosti ponovljenih doza provedenih u miševa, štakora i pasa, nalazi povezani s atazanavirom općenito su bili ograničeni na jetru i uključivali su općenito minimalna do blaga povišenja serumskog bilirubina i jetrenih enzima, hepatocelularnu vakuolizaciju i hipertrofiju te, samo u ženki miša, nekrozu pojedinačnih jetrenih stanica.
In repeat-dose toxicology studies in animals, hepatic effects (Kupffer-cell hypertrophy/ hyperplasia, mononuclear cell infiltrates and bile duct hyperplasia) and adrenal gland effects (changes in cytoplasmic vacuolation and adrenal cortical hypertrophy/hyperplasia) were observed at exposures similar or slightly higher than the clinical AUC exposure.
U toksikološkim ispitivanjima s ponovljenim dozama na životinjama primijećeni su učinci na jetru (hipertrofija/hiperplazija Kupfferovih stanica, mononuklearni stanični infiltrati i hiperplazija žučnih vodova) te učinci na nadbubrežnu žlijezdu (promjene u citoplazmatskoj vakuolizaciji te hipertrofija/hiperplazija kore nadbubrežne žlijezde) s izloženošću koja je nešto veća od kliničke AUC izloženosti.
In repeated dose toxicity studies the liver appeared as a target organ for toxicity in the different species tested.
U ispitivanjima toksičnosti ponovljene doze, jetra se činila ciljnim organom toksičnosti u različitih ispitanih vrsta.
In repeated dose toxicity studies with entacapone, anaemia most likely due to iron chelating properties of entacapone was observed.
U studijama toksičnosti ponovljenih doza s entakaponom opažena je anemija, najvjerojatnije zbog svojstva entakapona da stvara kelate sa željezom.
In repeated dose toxicity studies, the only finding of relevance was an increase in melanin pigmentation in the dog, which is consistent with the active substance’s pharmacological activity.
U ispitivanju toksičnosti ponovljenih doza, jedini značajan nalaz bilo je povećanje melaninske pigmentacije u pasa, što je konzistentno s farmakološkim djelovanjem djelatne tvari.
In replacement therapy the dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response.
Kod nadomjesne terapije doziranje treba individualizirati za svakog bolesnika ovisno o farmakokinetici i kliničkom odgovoru.
In replacement therapy the dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response.
U nadomjesnoj terapiji doziranje će biti prilagođeno ovisno o farmakokinetici i kliničkoj reakciji.
In replicating cells this leads to DNA double strand breaks (DSBs) when replication forks meet the PARP-DNA adduct.
U replicirajućim stanicama to uzrokuje dvolančane lomove DNK kada replikacijske vilice naiđu na PARP-DNK aduktom.
In reproduction studies in cynomolgus monkeys, subcutaneous doses up to 75 mg/kg per week (at least 8 times the highest recommended clinical dose in mg/kg over a 4-week period) did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on foetal or neonatal growth when administered throughout late gestation, delivery and nursing.
U reprodukcijskim studijama cynomolgus majmuna supkutane doze do 75 mg/kg tjedno (najmanje 8 puta veća od najveće preporučene doze u mg/kg tijekom 4 tjedna) nisu izazvale toksičnost kod majke, embriotoksičnost ili teratogenost tijekom primjene kroz period organogeneze te nisu izazvale nuspojave vezane uz fetalni i neonatalni rast tijekom primjene kroz period kasne trudnoće, porođaja i dojenja.
In reproduction studies in cynomolgus monkeys, subcutaneous doses up to 75 mg/kg per week (at least 8 times the highest recommended clinical dose in mg/kg over a 4-week period) did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on foetal or neonatal growth when administered throughout late gestation, delivery and nursing.
U reprodukcijskim studijama cynomolgus majmuna supkutane doze do 75 mg/kg tjedno (najmanje 8 puta veća od preporučene kliničke doze u mg/kg tijekom 4 tjedna) nisu izazvale toksičnost kod majke, embriotoksičnost ili teratogenost tijekom primjene kroz period organogeneze te nisu izazvale nuspojave vezane uz fetalni i neonatalni rast tijekom primjene kroz period kasne trudnoće, porođaja i dojenja.
In reproduction studies performed with nepafenac in rats, maternally toxic doses ≥ 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced foetal weights and growth, and reduced foetal survival.
U ispitivanjima reprodukcije koja su s nepafenakom provedena u štakora, doze ≥10 mg/kg, koje su bile toksične po ženku, bile su povezane s distocijom, povećanim gubitkom nakon implantacije, smanjenom težinom i rastom fetusa te sa smanjenim preživljavanjem fetusa.
In reproduction toxicity studies decreased fertility in male rats was observed.
U ispitivanjima reprodukcijske toksičnosti opažena je smanjena plodnost mužjaka štakora.
In reproduction toxicity tests, the incidence of post-implantation losses, resorptions and foetal body weight retardation occurred at doses not producing maternal toxicity in the rabbit studies.
U testovima reproduktivne toksičnosti, incidencija poslijeimplantacijskih gubitaka, resorpcije i smanjene fetalne tjelesne težine nastupila je pri dozama koje nisu bile toksične za majke u ispitivanjima na kunićima.
In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure.
U ispitivanjima reproduktivne i razvojne toksičnosti na glodavcima i kunićima nisu primijećeni teratogeni učinci, ali je primijećeno povećanje broja mrtvorođenih mladunaca i broja smrti u peripartalnom razdoblju te lagano smanjenje veličine živog legla i smanjenje tjelesne težine mladunaca kod izloženosti ženki toksičnim dozama za štakore, a koje odgovaraju razinama sistemske izloženosti sličnim očekivanoj kliničkoj izloženosti.
In reproductive studies in rats by the intravenous route, ibandronic acid decreased sperm counts at doses of 0.3 and 1 mg/kg/day and decreased fertility in males at 1 mg/kg/day and in females at 1.2 mg/kg/day.
U reproduktivnim ispitivanjima na štakorima koji su lijek primali intravenskim putem, ibandronatna kiselina je smanjila broj spermija pri dozama od 0,3 i 1 mg/kg na dan te smanjila plodnost u mužjaka pri dozi od 1 mg/kg na dan, a u ženki pri dozi od 1,2 mg/kg na dan.
In reproductive studies in rats by the oral route effects on fertility consisted of increased preimplantation losses at dose levels of 1 mg/kg/day and higher.
U reproduktivnim ispitivanjima peroralne primjene na štakorima, djelovanje na plodnost obuhvaćalo je povećani gubitak prije implantacije pri dozama od mg/kg na dan i višim.
In reproductive studies in rats by the oral route, effects on fertility consisted of increased preimplantation losses at dose levels of 1 mg/kg/day and higher.
U reproduktivnim ispitivanjima peroralne primjene na štakorima, djelovanje na plodnost obuhvaćalo je povećani gubitak prije implantacije pri dozama od mg/kg na dan i višim.
In reproductive studies in rats by the oral route, ibandronic acid decreased fertility.
U reproduktivnim ispitivanjima peroralne primjene na štakorima, ibandronatna kiselina smanjila je njihovu plodnost.
In reproductive toxicity studies in animals, dolutegravir was shown to cross the placenta.
Istraživanja reproduktivne toksičnosti na životinjama pokazala su da dolutegravir prolazi kroz placentu.
In reproductive toxicity studies in animals, dolutegravir, lamivudine and abacavir were shown to cross the placenta.
Ispitivanja reproduktivne toksičnosti na životinjama pokazala su da dolutegravir, lamivudin i abakavir prolaze kroz placentu.
In reproductive toxicity studies in rats and rabbits, trametinib induced maternal and developmental toxicity.
U ispitivanjima reproduktivne toksičnosti na štakorima i kunićima trametinib je izazvao toksičnost za majku i razvojnu toksičnost.
In reproductive toxicity studies with fosamprenavir in rats, male fertility was not affected, but in females gravid uterine weights, numbers of ovarian corpora lutea and uterine implantation sites were reduced.
U ispitivanjima reproduktivne toksičnosti fosamprenavira provedenim na štakorima nije bilo utjecaja na mušku plodnost, ali kod ženki je došlo do povećanja težine gravidnih uterusa te smanjenja broja žutih tijela u ovarijima, kao i mjesta intrauterine implantacije.
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
U studijama o reproduktivnoj toksičnosti u štakora nije zabilježen učinak na fertilitet u mužjaka i ženki, dok je u ženki primijećena super-ovulacija i lagano učestaliji gubitak prije implantacije.
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
U studijama o reproduktivnoj toksičnosti u štakora nije zabilježen učinak na fertilitet u mužjaka i ženki, dok je u ženki primijećena superovulacija i lagano učestaliji gubitak prije implantacije.
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
U studijama o reproduktivnoj toksičnosti u štakora nije zabilježen učinak na fertilitet u mužjaka i ženki, dok je u ženki primijećena superovulacija i malo povećani gubitak prije implantacije.
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
U studijama o reproduktivnoj toksičnosti u štakora nije zabilježen učinak na fertilitet u mužjaka i ženki, dok je u ženki primjećena superovulacija i malo povećani gubitak prije implantacije.
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
U studijama reproduktivne toksičnosti topotekana u štakora nije zabilježen učinak na fertilitet u mužjaka i ženki, dok je u ženki primijećena super-ovulacija i lagano učestaliji gubitak prije implantacije.
In reproductive toxicology studies, evidence of impaired fertility was seen in rats.
U ispitivanjima reproduktivne toksičnosti kod štakora su uočeni poremećaji plodnosti.
In reproductive toxicology studies, evidence of impaired fertility was seen in rats.
U ispitivanjima reproduktivne toksičnosti na štakorima su uočeni poremećaji plodnosti.
In responders, this response was maintained during 48 weeks. (see section 4.2).
U bolesnika u kojih je zabilježen odgovor na liječenje on se održao kroz 48 tjedana (vidjeti dio 4.2.).
In response to subcutaneous doses of Preotact (100 micrograms parathyroid hormone), serum total calcium levels increase gradually and reach peak concentration (mean increase in 129 patients, 0.15 mmoll) at approximately 6 to 8 hours after dosing.
Kao odgovor na supkutanu dozu Preotacta (100 mikrograma paratireoidnog hormona), ukupna razina kalcija u serumu postepeno se povećava i dostiže vršnu koncentraciju (srednja vrijednost povećanja kod 129 bolesnika, 0,15 mmol/l ) približno 6 do 8 sati nakon doziranja.
In retigabine-treated patients in the pooled dataset, confusional state was reported in 9% of patients, hallucinations in 2% of patients and psychotic disorders in 1% of patients (see section 4.4).
U skupnim podacima bolesnika koji su primali retigabin, u njih 9% zabilježeno je konfuzno stanje, halucinacije u 2% bolesnika i psihotični poremećaji u 1% bolesnika (vidjeti dio 4.4).
In retrospective meta-analyses including the data of both studies, a statistically significant overall treatment effect was found (p=0.0076; 8.0 million IU Extavia versus all placebo patients).
U retrospektivnim meta-analizama koje su uključivale podatke iz oba ispitianja otkriven je statistički značajan ukupan terapijski učinak (p=0,0076; 8,0 milijuna IU Extavije naspram svih bolesnika koji su primali placebo).
In rhDNase users in study 301 the relative change in FEV1 % predicted from baseline across 26 weeks of treatment was 2.83 (95% CI -0.62, 6.27).
Za osobe koje uzimaju rhDNase u ispitivanju 301, procijenjena relativna postotna promjena FEV1 % u odnosu na početnu vrijednost tijekom 26 tjedana iznosila je 2,83 (95% CI -0,62, 6,27).
In Rheumatoid Arthritis and in CAPS, your body produces too much of a cytokine called interleukin-1.
Ako imate reumatoidni artritis ili CAPS, Vaše tijelo stvara previše citokina zvanog interleukin-1.
In rheumatoid arthritis premedication with glucocorticoids should also be administered before each infusion of MabThera in order to reduce the frequency and severity of IRRs (see section 4.2 and section 4.8).
Također se, radi smanjenja učestalosti i težine infuzijskih reakcija, prije svake infuzije lijeka MabThera u liječenju reumatoidnog artritisa mora primijeniti premedikacija glukokortikoidima (vidjeti dio 4.2 i dio 4.8).
In rheumatoid arthritis, Cimzia with methotrexate was more effective than placebo with methotrexate.
Kod reumatoidnog artritisa lijek Cimzia s metotreksatom bio je djelotvorniji od placeba s metotreksatom.
In rheumatoid arthritis, Leflunomide Winthrop has been studied in four main studies involving over 2,000 patients, in which it was compared with placebo (a dummy treatment), or with methotrexate or sulphasalazine (other medicines used to treat rheumatoid arthritis).
U slučaju reumatoidnog artritisa, Leflunomide Winthrop je ispitan u četiri glavna ispitivanja koja su obuhvatila više od 2 000 bolesnika, u kojih je lijek uspoređen s placebom (liječenjem bez djelatne tvari) ili s metotreksatom ili sulfasalazinom (drugim lijekovima koji se koriste za liječenje reumatoidnog artritisa).
In rheumatoid arthritis, Leflunomide Winthrop was more effective than placebo and as effective as sulphasalazine.
U slučaju reumatoidnog artritisa, lijek Leflunomide Winthrop bio je djelotvorniji od placeba te podjednako djelotvoran kao sulfazalazin.
In rheumatoid arthritis, methotrexate is continued while using Humira.
Kod reumatoidnog artritisa, primjena metotreksata se nastavlja za vrijeme primjene lijeka Humira.
In rheumatoid arthritis, Orencia has been studied in four main studies involving a total of 1,733 adults.
U slučaju reumatoidnog artritisa, Orencia je ispitana u tri glavna ispitivanja koja su obuhvatila ukupno 1733 odrasle osobe.
In rheumatoid arthritis, Orencia was more effective than placebo in improving symptoms in all of the studies.
U slučaju reumatoidnog artritisa, lijek Orencia je u svim ispitivanjima bio djelotvorniji od placeba u ublažavanju simptoma bolesti.
In rheumatoid arthritis, psoriatic arthritis and Crohn's disease patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab.
Ima naznaka da istodobna primjena metotreksata i drugih imunomodulatora u bolesnika s reumatoidnim artritisom, psorijatičnim artritisom i Crohnovom bolešću smanjuje stvaranje protutijela na infliksimab i povećava koncentraciju infliksimaba u plazmi.
In rheumatoid arthritis, RoActemra can be given as an infusion into a vein or as an injection under the skin.
U slučaju reumatoidnog artritisa, RoActemra se može primjenjivati kao infuzija u venu ili kao injekcija pod kožu.
In rheumatoid arthritis, the greatest reductions in symptoms were seen in the studies examining Humira as an add-on to methotrexate: around two-thirds of the patients adding Humira had at least a 20% reduction in symptoms after six months, compared with a quarter of those adding placebo.
Kod reumatoidnog artritisa najveće ublažavanje simptoma zabilježeno je tijekom ispitivanja u kojima je lijek Humira ispitivan kao dodatak metotreksatu: kod oko dvije trećine bolesnika koji su dodavali lijek Humira simptomi su ublaženi za barem 20 % nakon šest tjedana, u usporedbi s jednom četvrtinom kod bolesnika koji su dodavali placebo.
In rheumatoid arthritis, your body produces too much of a cytokine called interleukin-1.
U reumatoidnom artritisu, Vaše tijelo stvara previše citokina zvanog interleukin-1.
In rheumatoid arthritis: leflunomide therapy is usually started with a loading dose of 100 mg once daily for 3 days.
U bolesnika s reumatoidnim artritisom: terapija leflunomidom započinje primjenom udarne doze od 100 mg jedanput na dan tijekom 3 dana.
In rheumatoid arthritis: leflunomide therapy is usually started with a loading dose of 100 mg once daily for 3 days.
U bolesnika s reumatoidnim artritisom: terapiju leflunomidom započinje primjenom udarne doze od 100 mg jedanput na dan tijekom 3 dana.
In RHODOS and the EAP in LHON, a total of 3 patients between the ages of 9 and 11 years and 27 patients between the ages of 12 and 17 years received idebenone at 900 mg/day for up to 33 months.
U ispitivanjima RHODOS i EAP u bolesnika s LHON-om, ukupno 3 bolesnika u dobi između 9 i 11 godina te 27 bolesnika u dobi između 12 i 17 godina primilo je idebenon u dozi od ≥ 900 mg/dan tijekom razdoblja od najviše 33 mjeseca.
in rifabutin exposure and especially in
očekivati i povećanje izloženosti rifabutinu a
In rodent models, stiripentol appears to increase brain levels of gamma-aminobutyric acid (GABA) - the major inhibitory neurotransmitter in mammalian brain.
Čini se da u štakora, stiripentol povećava razine gama-aminomaslačne kiseline (GABA) u mozgu – glavnog inhibitornog neurotransmitera u mozgu sisavaca.
In rodents, varenicline is transferred through the placenta and excreted in milk.
U glodavaca vareniklin prolazi kroz placentu i izlučuje se u mlijeko.
In safety pharmacology studies in dogs, ONIVYDE had no effect on cardiovascular, hemodynamic, electrocardiographic, or respiratory parameters at doses up to 21 mg/kg (420 mg/m2).
U ispitivanjima sigurnosne farmakologije na psima, ONIVYDE nije imao učinak na kardiovaskularne, hemodinamičke, elektrokardiografske ili respiratorne parametre pri dozama do 21 mg/kg (420 mg/m2).
In sALCL, Adcetris has been studied in one main study in 58 sALCL patients whose cancer had come back or had not responded to treatment.
U pogledu sALCL-a, lijek Adcetris ispitivan je u jednom glavnom ispitivanju kojim je bilo obuhvaćeno 58 bolesnika oboljelih od sALCL-a u kojih se rak ponovno javio ili u kojih nije bilo pozitivnog odgovora na prethodno liječenje.
In saliva vector DNA was still detectable up to 12 weeks; in urine up to 10 weeks and in semen up to 26 weeks.
U slini je još bilo moguće pronaći DNK vektor do 12 tjedana nakon injiciranja, u urinu do 10 tjedana, a u spermi do 26 tjedana.
In SAWYER trial (BO25341) the incidence of treatment-induced/enhanced anti-rituximab antibodies was similar in the two treatment arms; 6.7% intravenous vs.
U ispitivanju SAWYER (BO25341), incidencija liječenjem izazvanog/pospješenog stvaranja antitijela na rituksimab bila je slična u obje liječene skupine: 6,7% u skupini liječenoj intravenskom formulacijom te 2,4% u skupini koja je primala supkutanu formulaciju.
In SC- II, 656 patients were randomized 2:1 to tocilizumab subcutaneous 162 mg every other week or placebo, in combination with non-biologic DMARD(s).
U ispitivanju SC-II, 656 bolesnika randomizirano je u omjeru 2:1 u skupinu koja je primala tocilizumab u supkutanoj dozi od 162 mg jedanput svaka dva tjedna ili placebo, u kombinaciji s nebiološkim DMARD-ovima.
In SC-1, the ACR 20 response rates at Day 169 for subcutaneous and intravenous abatacept were respectively 78.3% (472/603 SC) and 76.0% (456/600 IV) in patients < 65 years, versus 61.1% (55/90 SC) and 74.4% (58/78 IV) for patients ≥ 65 years.
U Ispitivanju SC-I udio odgovora ACR20 169. dana iznosio je 78,3% (472/603) kod supkutane primjene i 76,0% (456/600) kod intravenske primjene u bolesnika mlađih od 65 godina, u odnosu na 61,1% (55/909) kod supkutane primjene te 74,4% (58/78) kod intravenske primjene u bolesnika u dobi od ≥ 65 godina.